Ann: Monthly Activities/Appendix 4C Cash Flow Report, page-12

but they get paid bonuses throughout the developing period based on achieving certain targets BUT SP does not form part of the KPI's. Therefore not in their interest to find that key product that will earn a nice return.

stick to seeking expiring patents then develop that in a generic way and enter the generic market - so what about competitors the bonuses are no doubt just based on developing the product then no doubt on FDA approval then to market - rinse repeat. Huge pipeline but all generic in nature and targeted towards small consumer markets!